Mechanisms and Factors Responsible for the Inhibition of Transposons During Fetal Gonad Development in Humans

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DIJON · Jun 23, 2014

Keywords

ClinConnect Summary

This clinical trial is investigating how certain genetic elements, called transposons, behave during the development of male gonads (testes) in fetuses. Transposons are sequences of DNA that can move around within the genome, and this study aims to understand how their activity is controlled during crucial stages of fetal development. The researchers will analyze tissue samples from male fetuses that are being terminated for medical or voluntary reasons at different stages of pregnancy. They will look at the gonads and some other tissues to see how transposons and their inhibitors are expressed.

To be eligible for this study, participants must be parents who can provide consent for their male fetus, which should be between 10 and 37 weeks of pregnancy. Participants will not be able to join if they do not have health insurance, if the fetus has certain genetic conditions, or if there are malformations in the genital organs. The study is expected to take 36 months and will involve around 30 patients. It's important to note that this trial is currently recruiting participants, and those involved will contribute to understanding important biological processes in fetal development.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Couple or mother who has provided written informed consent
• • Foetus between 10 and 37 weeks of amenorrhea (WA)
• • Male foetus
• • Foetus obtained following medical termination of pregnancy or voluntary termination of pregnancy
• Exclusion Criteria:
• • persons without national health insurance cover
• • foetus presenting aneuploidy
• • foetus presenting a malformation of the genital organs